Business
Patent Grant in the United States
Patent Grant in the United States.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 8644W Evgen Pharma PLC 14 February 2017 \n\n \n\n\n\n\nFor immediate release\n\n\n14 February 2017\n\n\n\n\n \n \n \nEvgen Pharma plc \n (\"Evgen Pharma\" or \"the Company\")\n Patent Grant in the United States\nEvgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce that the United States Patent and Trademark Office has granted a patent that significantly broadens and extends the Company's intellectual property around its lead product, SFX-01.\nSFX-01 is a synthetic version of the naturally occurring compound sulforaphane, which has been stabilised in an alpha-cyclodextrin lattice. The current patent protection is composition of matter and runs until 2028. This new patent, granted today under number US9,567,405 and entitled Method of Synthesizing Sulforaphane, covers the manufacturing process and runs until 2033.\nThe exclusive worldwide rights to the patent are held by Evgen Pharma under the terms of a licence agreement with PharmAgra Labs Inc., the US laboratory that invented SFX-01. \nEvgen Pharma is currently conducting two Phase II trials of SFX-01, one in advanced breast cancer and one in a type of stroke called subarachnoid haemorrhage.\nDr Stephen Franklin, CEO of Evgen Pharma, commented: \"This patent grant extends our intellectual property protection in the world's largest pharmaceutical market and is the first of a potentially broad geographical spread of patents that are pending in Europe, Japan, India, China, Canada, Brazil and Australia\".\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.\n \nEnquiries:\n \n\n\n\n\nEvgen Pharma plc\nDr Stephen Franklin, CEO\nwww.evgen.com\n\n\nc/o +44 (0) 20 7466 5000\n \n\n\n\n\n \n\n\n \n\n\n\n\nBuchanan\nMark Court, Sophie Cowles, Stephanie Watson\n\n\n+44 (0) 20 7466 5000\n \n\n\n\n\n \n\n\n \n\n\n\n\nNorthland Capital Partners Limited\nMatthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance)\nJohn Howes and Rob Rees (Corporate Broking)\n\n\n+44 (0) 20 3861 6625\n\n\n\n \n \n \n\n\n\n \nNotes for editors:\nAbout Evgen Pharma plc\nEvgen Pharma is a clinical stage drug developmen...